Epidermoid Cancer Development in Esophageal Achalasia
Launched by SANDRO MATTIOLI · May 23, 2018
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a condition called esophageal achalasia, which affects the swallowing process, might increase the risk of developing a type of cancer known as epidermoid carcinoma in the esophagus. Researchers want to learn more about how often this cancer occurs in patients with achalasia and what factors might contribute to its development. The goal is to gather important information that can help improve patient care and early detection of cancer in those with achalasia.
To participate in this trial, individuals must be diagnosed with primary esophageal achalasia through tests such as imaging, endoscopy, and manometry (a test that measures muscle contractions in the esophagus). People with a different condition called pseudoachalasia are not eligible. The trial is currently recruiting participants of all ages and genders. Those who join the study will help contribute to valuable research that could lead to better understanding and treatment options for patients with achalasia and related cancer risks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosis of primary esophageal achalasia achieved by means of radiology, endoscopy and manometry
- Exclusion Criteria:
- • pseudoachalasia
About Sandro Mattioli
Sandro Mattioli is a dedicated clinical trial sponsor specializing in the development and execution of innovative research initiatives aimed at advancing medical science and improving patient outcomes. With a strong commitment to ethical standards and regulatory compliance, Mattioli oversees a diverse portfolio of clinical studies across various therapeutic areas. The organization emphasizes collaboration with healthcare professionals, academic institutions, and industry partners to facilitate cutting-edge research and ensure the integrity of clinical data. Through a patient-centered approach, Sandro Mattioli strives to bring new therapies to market that address unmet medical needs and enhance the quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cotignola, Ra, Italy
Patients applied
Trial Officials
Sandro Mattioli, MD
Principal Investigator
Department of Medical and Surgical Sciences-Alma Mater Studiorum-Università di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials